中央明确明年优化药品集中采购，可以从哪些方面入手？

Group 1 - The core focus of the Central Economic Work Conference held on December 10-11 in Beijing is to enhance efforts in anti-involution, including optimizing drug centralized procurement and deepening medical insurance payment reform [1] - Since the launch of the "4+7" centralized procurement pilot by the National Healthcare Security Administration in November 2018, eleven batches of drug procurement have been conducted, successfully procuring 490 types of drugs [1] - The goals of drug procurement include reducing the economic burden on insured individuals by cutting out intermediaries and improving the efficiency of medical insurance fund usage, while also pushing companies towards innovation [1] Group 2 - The eleventh batch of national drug centralized procurement, which concluded on October 27, 2025, included 55 types of drugs across various common therapeutic areas, achieving the expected goals of "stabilizing clinical use, ensuring quality, countering involution, and preventing collusion" [2] - The procurement process has been optimized to better match selected products with medical institution needs, raise the qualification thresholds for bidding companies, encourage rational pricing, and standardize bidding behavior [2] - There is ongoing high interest in how to further counter involution in future drug procurements, with suggestions for establishing a minimum bidding price to provide more certainty for companies [3] Group 3 - Experts suggest that the procurement rules can be further strengthened around the four dimensions of "stabilizing clinical use, ensuring quality, countering involution, and preventing collusion," including potentially setting a minimum price for selected drugs [3] - There is a proposal to explore separating medical insurance payment standards from drug prices, allowing for a situation where non-selected drugs could be priced above the insurance payment standard, ensuring the availability of off-patent original drugs while requiring lower prices for non-selected options [3]